Genpact Has Been Working With embecta's To Support Its Spin-Off Into An Independent Diabetes Care Company
Author: Benzinga Newsdesk | July 29, 2024 08:17am
Genpact's deep domain knowledge and data expertise enables embecta's vision to make a meaningful impact in the healthcare sector
NEW YORK, July 29, 2024 /PRNewswire/ -- Genpact (NYSE:G), a global professional services and solutions firm delivering outcomes that shape the future, has been working with embecta (NASDAQ:EMBC), a global diabetes care company, to support its spin-off from Becton Dickinson and Company (BD) and subsequent evolution as an independent leader in the diabetes technology market.
Posted In: EMBC G